The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study)
Open accessAbstract
Objective: To evaluate the efficacy and tolerability of single pulse transcranial magnetic stimulation (sTMS) for the preventive treatment of migraine. Background: sTMS was originally developed for the acute treatment of migraine with aura. Open label experience has suggested a preventive benefit. The objective of this trial was to evaluate the efficacy and tolerability of sTMS for migraine prevention. Methods: The eNeura SpringTMS Post-Market Observational U.S. Study of Migraine (ESPOUSE) Study was a multicenter, prospective, open label, observational study. From December 2014 to March 2016, patients with migraine (n = 263) were consented to complete a 1-month baseline headache diary followed by 3 months of treatment. The treatment protocol consisted of preventive (four pulses twice daily) and acute (three pulses repeated up to three times for each attack) treatment. Patients reported daily headache status, medication use, and device use with a monthly headache diary. The primary endpoint, mean reduction of headache days compared to baseline, was measured over the 28-day period during weeks 9 to 12. The primary endpoint was compared to a statistically-derived placebo estimate (performance goal). Secondary endpoints included: 50% responder rate, acute headache medication consumption, HIT-6, and mean reduction in total headache days from baseline of any intensity. Results: Of a total of 263 consented subjects, 229 completed a baseline diary, and 220 were found to be eligible based on the number of headache days. The device was assigned to 217 subjects (Safety Data Set) and 132 were included in the intention to treat Full Analysis Set. For the primary endpoint, there was a −2.75 ± 0.40 mean reduction of headache days from baseline (9.06 days) compared to the performance goal (−0.63 days) ( p < 0.0001). The 50% responder rate of 46% (95% CI 37%, 56%) was also significantly higher ( p < 0.0001) than the performance goal (20%). There was a reduction of −2.93 (5.24) days of acute medication use, headache impact measured by HIT-6, −3.1 (6.4) ( p < 0.0001), and total headache days of any intensity −3.16 days (5.21) compared to the performance goal (−0.63 days) ( p < 0.0001). The most common adverse events were lightheadedness (3.7%), tingling (3.2%), and tinnitus (3.2%). There were no serious adverse events. Conclusions: This open label study suggests that sTMS may be an effective, well-tolerated treatment option for migraine prevention. Trial registration number: NCT02357381
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The International Classification of Headache Disorders, 3rd edition (beta version)
Headache Classification Committee of the International Headache Society (IHS) (2013) · Cephalalgia · doi:10.1177/0333102413485658 · Cited by 8,229
Vos, T., Allen, C., Arora, M., Barber, R. M., Bhutta, Z. A., Brown, A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31678-6 · Cited by 7,253
Migraine prevalence, disease burden, and the need for preventive therapy
Lipton, R. B., Bigal, M. E., Diamond, M., Freitag, F., Reed, M. L., & Stewart, W. F. (2007) · Neurology · doi:10.1212/01.wnl.0000252808.97649.21 · Cited by 2,337
Self-citationSociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers
Buse, D. C., Manack, A., Serrano, D., Turkel, C., & Lipton, R. B. (2010) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.192492 · Cited by 622
Self-citationTherapeutic application of repetitive transcranial magnetic stimulation: a review
Wassermann, E. M., & Lisanby, S. H. (2001) · Clinical Neurophysiology · doi:10.1016/s1388-2457(01)00585-5 · Cited by 601
A neural mechanism for exacerbation of headache by light
Noseda, R., Kainz, V., Jakubowski, M., Gooley, J. J., Saper, C. B., Digre, K., & Burstein, R. (2010) · Nature Neuroscience · doi:10.1038/nn.2475 · Cited by 565
rTMS of the prefrontal cortex in the treatment of chronic migraine: A pilot study
Brighina, F., Piazza, A., Vitello, G., Aloisio, A., Palermo, A., Daniele, O., & Fierro, B. (2004) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2004.08.008 · Cited by 269
Gaul, C., van Doorn, C., Webering, N., Dlugaj, M., Katsarava, Z., Diener, H.-C., & Fritsche, G. (2011) · The Journal of Headache and Pain · doi:10.1007/s10194-011-0348-y · Cited by 156 · cited 1×
“Poor adherence is most commonly a result of poor outcomes, such as inefficacy or side effects (33,34).”
BackgroundBhola, R., Kinsella, E., Giffin, N., Lipscombe, S., Ahmed, F., Weatherall, M., & Goadsby, P. J. (2015) · The Journal of Headache and Pain · doi:10.1186/s10194-015-0535-3 · Cited by 138 · cited 9×
“Additional analyses compared ESPOUSE results to post market observational data collected in the UK study for preventive treatment of chronic migraine (16).”
BackgroundMethodResultInfluentialSelf-citationConforto, A. B., Amaro, E., Gonçalves, A. L., Mercante, J. P., Guendler, V. Z., Ferreira, J. R., Kirschner, C. C., & Peres, M. F. (2014) · Cephalalgia · doi:10.1177/0333102413515340 · Cited by 125 · cited 1×
“Conforto and colleagues found that stimulation of the dorsolateral prefrontal cortex (DLPFC) using a tabletop clinic-based rTMS did not decrease headache days in migraine (14).”
Method
Cited by
Ailani, J., Burch, R. C., Robbins, M. S., & the Board of Directors of the American Headache Society (2021) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.14153 · Cited by 766
Self-citationAmerican Headache Society (2019) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.13456 · Cited by 567
Dodick, D. W. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30478-1 · Cited by 557
Self-citationMechanisms of migraine as a chronic evolutive condition
Andreou, A. P., & Edvinsson, L. (2019) · The Journal of Headache and Pain · doi:10.1186/s10194-019-1066-0 · Cited by 289
Lloyd, J. O., Hill, B., Murphy, M., Al-Kaisy, A., Andreou, A. P., & Lambru, G. (2022) · The Journal of Headache and Pain · doi:10.1186/s10194-022-01428-6 · Cited by 21
Metadata
- Authors
- Starling, A. J., Tepper, S. J., Marmura, M. J., Shamim, E. A., Robbins, M. S., Hindiyeh, N., Charles, A. C., Goadsby, P. J., Lipton, R. B., Silberstein, S. D., Gelfand, A. A., Chiacchierini, R. P., & Dodick, D. W.
- Venue
- Cephalalgia
- Publisher
- SAGE Publications
- Published
- 2018-03-04
- Volume
- 38
- Issue
- 6
- Pages
- 1038-1048
- ISSN
- 0333-1024 (ISSN-L)
- 1468-2982
- OpenAlex
- W2791404053
- Cited by
- 162
- References
- 10
- FWCI
- 15.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.